Cytosorbents CorpNASDAQ:CTSO
- LAST PRICE0.8705
- TODAY'S CHANGE (%)-0.1295 (-12.9500%)
- Bid / Lots0.8700/ 1
- Ask / Lots0.9577/ 1
- Open / Previous Close0.9951 / 1.0000
- Day Range
- 52 Week Range
- Volume164,610
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CTSO |
|---|---|---|
| 09:32 ET | 442 | 0.9951 |
| 09:37 ET | 400 | 0.99 |
| 09:39 ET | 600 | 0.99 |
| 09:42 ET | 7693 | 0.99 |
| 09:44 ET | 1500 | 0.98 |
| 09:48 ET | 400 | 0.98 |
| 09:50 ET | 100 | 0.99 |
| 09:53 ET | 100 | 0.985 |
| 09:55 ET | 275 | 0.9848 |
| 10:04 ET | 5222 | 0.98 |
| 10:11 ET | 100 | 1.0048 |
| 10:15 ET | 1500 | 0.97 |
| 10:18 ET | 6916 | 0.9651 |
| 10:20 ET | 6342 | 0.97 |
| 10:27 ET | 200 | 0.98 |
| 10:36 ET | 202 | 0.99 |
| 10:38 ET | 250 | 0.9899 |
| 10:40 ET | 620 | 0.9851 |
| 10:42 ET | 350 | 0.98 |
| 10:44 ET | 100 | 0.9798 |
| 10:49 ET | 1750 | 0.97 |
| 10:51 ET | 157 | 0.97 |
| 10:56 ET | 100 | 0.98 |
| 10:58 ET | 843 | 0.97 |
| 11:09 ET | 3798 | 0.962 |
| 11:21 ET | 272 | 0.965 |
| 11:23 ET | 1000 | 0.962 |
| 11:27 ET | 5000 | 0.97 |
| 11:30 ET | 1302 | 0.962 |
| 11:34 ET | 400 | 0.96 |
| 11:54 ET | 100 | 0.965 |
| 11:56 ET | 100 | 0.96495 |
| 12:03 ET | 3400 | 0.97 |
| 12:10 ET | 2000 | 0.99 |
| 12:15 ET | 100 | 0.975 |
| 12:24 ET | 200 | 0.975 |
| 12:26 ET | 200 | 0.975 |
| 12:32 ET | 4503 | 0.96 |
| 12:35 ET | 887 | 0.9503 |
| 12:39 ET | 1936 | 0.9917 |
| 12:55 ET | 200 | 0.9501 |
| 01:00 ET | 100 | 0.975 |
| 01:08 ET | 100 | 0.975001 |
| 01:11 ET | 733 | 0.99 |
| 01:26 ET | 200 | 0.97 |
| 01:29 ET | 151 | 0.9699 |
| 01:31 ET | 1200 | 0.96 |
| 01:44 ET | 200 | 0.97 |
| 02:12 ET | 1000 | 0.9596 |
| 02:14 ET | 100 | 0.97 |
| 02:27 ET | 500 | 0.9601 |
| 02:30 ET | 650 | 0.9625 |
| 02:32 ET | 407 | 0.955 |
| 02:56 ET | 207 | 0.9501 |
| 02:57 ET | 893 | 0.9501 |
| 02:59 ET | 2817 | 0.95 |
| 03:01 ET | 291 | 0.9333 |
| 03:03 ET | 400 | 0.9333 |
| 03:06 ET | 2122 | 0.9154 |
| 03:08 ET | 400 | 0.9196 |
| 03:10 ET | 600 | 0.92 |
| 03:12 ET | 400 | 0.92 |
| 03:14 ET | 400 | 0.93 |
| 03:15 ET | 2653 | 0.9202 |
| 03:17 ET | 600 | 0.9155 |
| 03:19 ET | 400 | 0.9155 |
| 03:21 ET | 400 | 0.915 |
| 03:24 ET | 1376 | 0.91 |
| 03:26 ET | 495 | 0.9101 |
| 03:28 ET | 1223 | 0.91 |
| 03:30 ET | 10695 | 0.9011 |
| 03:32 ET | 1957 | 0.9011 |
| 03:33 ET | 900 | 0.901 |
| 03:35 ET | 990 | 0.9051 |
| 03:37 ET | 1000 | 0.9003 |
| 03:39 ET | 1393 | 0.9006 |
| 03:42 ET | 5258 | 0.9 |
| 03:44 ET | 11573 | 0.9 |
| 03:46 ET | 6277 | 0.9 |
| 03:48 ET | 1381 | 0.9 |
| 03:50 ET | 2039 | 0.9 |
| 03:51 ET | 3097 | 0.90475 |
| 03:53 ET | 1745 | 0.9026 |
| 03:55 ET | 3553 | 0.9 |
| 03:57 ET | 4562 | 0.9 |
| 04:00 ET | 18005 | 0.8705 |
Today
Oct 22, 2024
DJ Cytosorbents Is Maintained at Buy by EF Hutton, from 8:01AM ET on Tuesday Oct 22, 2024 by Dow Jones
8:01AM ET on Tuesday Oct 22, 2024 by Dow JonesFDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review, from 7:01AM ET on Tuesday Oct 22, 2024 by Dow Jones
7:01AM ET on Tuesday Oct 22, 2024 by Dow Jones
Oct 17, 2024
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results, from 7:00AM ET on Thursday Oct 17, 2024 by Dow Jones
7:00AM ET on Thursday Oct 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cytosorbents Corp | 54.4M | -1.7x | --- |
Bionano Genomics Inc | 24.2M | -0.1x | --- |
LENSAR Inc | 62.5M | -5.3x | --- |
STRATA Skin Sciences Inc | 12.3M | -1.3x | --- |
Aamaxan Transport Group Inc | 1.6K | 0.0x | --- |
Dynatronics Corp | 994.0K | -0.2x | --- |
Company Information
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
Contact Information
- Headquarters
- 305 COLLEGE ROAD EASTPRINCETON, NJ, United States 08540
- Phone
- 973-329-8885
- Fax
- ---
Executives
- Independent Non-Executive Chairman of the Board
- Michael Bator
- President, Chief Operating Officer
- Vincent Capponi
- Chief Executive Officer, Director
- Phillip Chan
- Chief Financial Officer
- Peter Mariani
- Chief Medical Officer
- Efthymios Deliargyris
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.4M |
|---|---|
Revenue (TTM) | $37.2M |
Shares Outstanding | 54.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.59 |
EPS | $-0.53 |
Book Value | $0.43 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -67.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
